LAMP Assay Developed to Diagnose High HBV DNA Levels
|
By LabMedica International staff writers Posted on 05 May 2021 |

Image: The AMPLIX real-time polymerase chain reaction system (Photo courtesy of Biosynex)
Worldwide, 257 million people are chronically infected with hepatitis B virus (HBV) and 887,000 annually die from cirrhosis or liver cancer. Since more than 95% of HBV-infected people live in low-income and middle-income countries (LMICs) and only 12-25% of infected people are eligible for anti-HBV therapy.
Loop-mediated isothermal amplification (LAMP) assay is a nucleic acid test (NAT) using DNA polymerase with high auto-cycling strand displacement activity and six specially designed primers. LAMP has the following characteristics allowing its use as a rapid, reliable and inexpensive point-of-care test in LMICs with a high amplification efficiency enabling rapid detection of nucleic acids.
A large team of medical scientists associated with the Pasteur Institute (Paris, France) designed Pan-genotypic primer sets on conserved HBV gene regions. Accuracy of LAMP to identify highly viremic patients was evaluated in 400 and 550 HBV-infected people in France and Senegal, respectively. Analytical validation was performed using real-time turbidimetric LAMP (Loopamp LA-500, Eiken Chemical, Japan). Viral loads were quantified using an AMPLIX real-time PCR (Biosynex, Illkirch-Graffenstaden France).
The team reported that their primers successfully detected eight major HBV genotypes/sub-genotypes (A1/2/3/B/C/D/E/F) with a detection limit ranging between 40-400 IU/mL. In France, the area under the receiver operating characteristic curve (AUROC), sensitivity and specificity of bead-based extraction and real-time turbidimetric LAMP were 0.95, 91.1% and 86.0%, respectively, to diagnose HBV DNA ≥20,000 IU/mL; and 0.98, 98.0% and 94.6% for ≥200,000 IU/mL. The performance did not vary by viral genotypes. In Senegal, using a field-adapted method, reagent-free boil-and-spin extraction and inexpensive end-point fluorescence detection, the AUROC, sensitivity and specificity were 0.95, 98.7% and 91.5%, respectively, to diagnose HBV DNA ≥200,000 IU/mL. The assay was not adapted to discriminate low-level viremia.
The authors concluded that they had developed a simple, rapid (60 minutes), and inexpensive (USD 8/assay) alternative to PCR to diagnose high viremia ≥200,000 IU/mL. HBV-LAMP may contribute to eliminating HBV mother-to-child transmission by identifying high-risk pregnant women eligible for antiviral prophylaxis in resource-limited countries. The study was published on April 7, 2021 in the journal Clinical Microbiology and Infection.
Related Links:
Pasteur Institute
Eiken Chemical
Biosynex
Loop-mediated isothermal amplification (LAMP) assay is a nucleic acid test (NAT) using DNA polymerase with high auto-cycling strand displacement activity and six specially designed primers. LAMP has the following characteristics allowing its use as a rapid, reliable and inexpensive point-of-care test in LMICs with a high amplification efficiency enabling rapid detection of nucleic acids.
A large team of medical scientists associated with the Pasteur Institute (Paris, France) designed Pan-genotypic primer sets on conserved HBV gene regions. Accuracy of LAMP to identify highly viremic patients was evaluated in 400 and 550 HBV-infected people in France and Senegal, respectively. Analytical validation was performed using real-time turbidimetric LAMP (Loopamp LA-500, Eiken Chemical, Japan). Viral loads were quantified using an AMPLIX real-time PCR (Biosynex, Illkirch-Graffenstaden France).
The team reported that their primers successfully detected eight major HBV genotypes/sub-genotypes (A1/2/3/B/C/D/E/F) with a detection limit ranging between 40-400 IU/mL. In France, the area under the receiver operating characteristic curve (AUROC), sensitivity and specificity of bead-based extraction and real-time turbidimetric LAMP were 0.95, 91.1% and 86.0%, respectively, to diagnose HBV DNA ≥20,000 IU/mL; and 0.98, 98.0% and 94.6% for ≥200,000 IU/mL. The performance did not vary by viral genotypes. In Senegal, using a field-adapted method, reagent-free boil-and-spin extraction and inexpensive end-point fluorescence detection, the AUROC, sensitivity and specificity were 0.95, 98.7% and 91.5%, respectively, to diagnose HBV DNA ≥200,000 IU/mL. The assay was not adapted to discriminate low-level viremia.
The authors concluded that they had developed a simple, rapid (60 minutes), and inexpensive (USD 8/assay) alternative to PCR to diagnose high viremia ≥200,000 IU/mL. HBV-LAMP may contribute to eliminating HBV mother-to-child transmission by identifying high-risk pregnant women eligible for antiviral prophylaxis in resource-limited countries. The study was published on April 7, 2021 in the journal Clinical Microbiology and Infection.
Related Links:
Pasteur Institute
Eiken Chemical
Biosynex
Latest Molecular Diagnostics News
- Genome Sequencing Provides Clues to Unexplained Recurrent Miscarriages
- Multimodal AI Blood Test Aims to Improve Early Lung Cancer Screening
- Protein-Based Classifier Shows Promise for Predicting Melanoma Treatment Outcomes
- Liquid Biopsy Gains FDA Approval to Guide Breast Cancer Combination Therapy
- FDA Clears Three-Virus Respiratory Panel for Anterior Nasal Swabs
- Whole Transcriptome Analysis Expands Understanding of Cancer Gene Fusions
- Fapon Showcases AI-Engineered Enzymes and RNA Workflows at AMP 2026
- AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health
- Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes
- Genetic Test Improves Risk Prediction for Open-Angle Glaucoma
- Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk
- Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment
- Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis
- AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026
- AMP 2026 Highlights Advances in Molecular Testing for Pediatric Diseases
- Liquid Biopsy Expands Insights Into Treatment Response and Tumor Alterations
Channels
Clinical Chemistry
view channel
Study Questions Uniform Stool-Test Cutoff Across Age Groups
Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more
Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine
Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more
Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreMolecular Diagnostics
view channelGenome Sequencing Provides Clues to Unexplained Recurrent Miscarriages
Recurrent pregnancy loss, defined as two or more miscarriages, affects about 5% of couples. In many cases, routine evaluation does not identify a cause, particularly when pregnancies have a normal chromosome... Read more
Genetic Test Improves Risk Prediction for Open-Angle Glaucoma
Glaucoma damages the optic nerve and is the leading cause of irreversible blindness worldwide. Because the disease often causes no early symptoms, about half of affected individuals remain undiagnosed... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more







